Korea Investment CORP Purchases 25,011 Shares of Eli Lilly and Company $LLY

Korea Investment CORP grew its position in Eli Lilly and Company (NYSE:LLY) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 701,407 shares of the company’s stock after acquiring an additional 25,011 shares during the quarter. Eli Lilly and Company accounts for about 1.5% of Korea Investment CORP’s holdings, making the stock its 11th largest position. Korea Investment CORP’s holdings in Eli Lilly and Company were worth $753,788,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the period. 10Elms LLP lifted its position in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the period. Finally, Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $33,000. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. Bank of America lifted their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,137.01 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a 50 day moving average price of $998.47 and a 200 day moving average price of $1,016.72. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,182.73. The stock has a market capitalization of $1.07 trillion, a PE ratio of 40.39, a price-to-earnings-growth ratio of 1.27 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 EPS. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.